Sissel Lønning Andresen explains how Pfizer Norway has been a pioneer of digital communication channels for years, what other Pfizer affiliates can learn from Norway in this field, and how it helped in terms of working through the COVID-19 pandemic. Andresen also highlights her market access priorities, with the gene therapies in Pfizer’s pipeline probably necessitating innovative pricing solutions, and makes a rallying cry for more clinical trials in Norway.
A concrete example of Pfizer Norway’s value is our pioneering of digital channels and how we utilize these channels to communicate with physicians and the public
